Welcome to our dedicated page for Biomarin Pharmaceutical SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioMarin Pharmaceutical Inc. filings document the regulatory record of a Nasdaq-listed biotechnology company focused on rare genetic diseases. Recent 8-K reports disclose operating and financial results, material events, material agreements, capital-structure matters and clinical or regulatory updates tied to products and programs such as VOXZOGO, PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA.
The company’s proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards and other governance disclosures. Filing records also cover common stock listing details, financing activities, acquisition-related disclosures and business updates affecting BioMarin’s commercial rare-disease portfolio and development pipeline.
BioMarin Pharmaceutical director Athena Countouriotis reported a routine equity compensation grant. On June 2, 2026, she acquired 7,490 shares of common stock in the form of restricted stock units, with no purchase price involved. Following this award, she directly holds 21,040 common shares.
BioMarin Pharmaceutical director Timothy P. Walbert reported an equity grant of 7,490 shares of common stock on June 2, 2026. The shares were received as restricted stock units granted on that date, with no purchase price involved, reflecting stock-based compensation rather than an open‑market trade.
Following the grant, Walbert directly holds 17,270 shares of BioMarin common stock. In addition, 416 shares are reported as indirectly held through Prairie Capital Ventures LLC. The filing does not show any sales or option exercises, only this award and an updated indirect holding line.
BioMarin Pharmaceutical director Maykin Ho reported an equity grant of company stock. On June 2, 2026, Ho acquired 7,490 shares of BioMarin common stock through a grant classified as restricted stock units, with no cash price per share.
Following this award, Ho directly holds 35,500 shares of BioMarin common stock. Because this was a compensation-related grant rather than an open-market trade, it mainly reflects ongoing equity-based director compensation rather than a change in personal investment stance.
HOMBACH ROBERT J. reported acquisition or exercise transactions in this Form 4 filing.
BIOMARIN PHARMACEUTICAL INC director Robert J. Hombach received a new equity award in the form of restricted stock units. On June 2, 2026, he was granted 7,490 shares of Common Stock as a compensation award, with no purchase price applicable to the grant.
Following this award, Hombach directly holds 49,360 shares of BioMarin common stock. This is a non-market transaction classified as a grant or award, rather than an open-market share purchase or sale.
BioMarin Pharmaceutical director Mark J. Enyedy received a stock-based compensation award. On June 2, 2026, he acquired 7,490 shares of common stock through a grant of restricted stock units, with no cash price per share. After this award, he directly holds 21,040 common shares.
Dere Willard H reported acquisition or exercise transactions in this Form 4 filing.
BIOMARIN PHARMACEUTICAL INC director Willard H. Dere received a grant of 7,490 shares of common stock in the form of restricted stock units on June 2, 2026. The grant is recorded at a price of $0.00 per share, reflecting that it is a compensation award rather than a market purchase.
Following this award, Dere directly holds 46,440 shares of BioMarin common stock as reported in this filing. The footnotes clarify that the transaction represents restricted stock units, with price not applicable.
CLARK IAN T reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical director Ian T. Clark received an equity grant. On June 2, 2026, he was awarded 7,490 restricted stock units tied to the company’s common stock, with no cash price per unit. Following this grant, he directly holds 14,490 common shares and units in total.
Bodem Barbara W. reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical Inc. director Barbara W. Bodem received a grant of 7,490 shares of common stock in the form of restricted stock units on June 2, 2026. The award had no purchase price, indicating it was compensation rather than an open-market buy. After this grant, she directly holds 21,045 common shares.
ANDERSON ELIZABETH M reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical director Elizabeth M. Anderson received a stock-based compensation grant. On June 2, 2026, she was awarded 7,490 shares of Common Stock in the form of restricted stock units at no cash cost, as the price is listed as not applicable.
After this grant, Anderson directly holds 41,940 shares of BioMarin Common Stock. This is a compensation-related award, not an open-market purchase or sale, and does not reflect a discretionary trading decision.
BioMarin Pharmaceutical Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the company’s 2017 Equity Incentive Plan, increasing the number of common shares reserved for issuance under the plan by 7,650,000 shares.
All ten director nominees were elected to serve until the next annual meeting. Stockholders also ratified the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of the company’s named executive officers.